Ambros Therapeutics Secures Notice Of Allowance From United States Patent And Trademark Office For CRPS Type 1 Treatment Patent

Ambros Therapeutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new U.S. patent application covering methods for selectively treating patients with Complex Regional Pain Syndrome Type 1 (CRPS-1), a rare orphan-designated disease. The approval of this patent strengthens Ambros’s intellectual property portfolio and enhances the potential for neridronate exclusivity through 2045.

The allowed patent application, titled “Methods of Selectively Treating Complex Regional Pain Syndrome Type 1 (CRPS-1) Using Bisphosphonate Derivatives,” was filed in July 2025. It covers the use of a positive triple-phase bone scan (TPBS) combined with specific characteristics of the warm CRPS subtype to identify patients most likely to respond to neridronate treatment. Ambros began enrolling patients in its pivotal Phase 3 CRPS-RISE trial (NCT07210515) in the first quarter of 2026, using these same selection criteria to determine trial eligibility.

Jay Hagan, Chief Executive Officer of Ambros Therapeutics, commented on the milestone, noting that the granting of this patent represents a significant step for the company and its orphan drug, neridronate. He emphasized that an enhanced IP portfolio positions Ambros to advance its pivotal program while potentially delivering meaningful benefits to patients with CRPS-1, as well as value to investors and other stakeholders.

Gail Cawkwell, M.D., Ph.D., Chief Medical Officer of Ambros Therapeutics, highlighted the innovative precision medicine approach represented by the patent. By combining positive triple-phase bone scan results with specific clinical features of CRPS-1, the method allows clinicians to identify patients who are significantly more likely to benefit from neridronate. She described this as an important advancement in the management of CRPS-1 and a meaningful step forward in improving outcomes for patients facing this challenging condition.